Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–107 of 107 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: interferon beta-1a Clear all

Conditions: Multiple Sclerosis
Interventions: ACTH, Methylprednisolone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis
Interventions: BIIB033, Placebo, Avonex; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 58 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more

Conditions: Multiple Sclerosis
Interventions: Avonex® monotherapy (6.0 MIU administered i.m. each week); Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis
Interventions: Rebif® New Formulation (RNF) using RebiSmartTM; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Healthy
Interventions: BIIB017 (PEGylated Interferon Beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Multiple Sclerosis
Interventions: Avonex and Topamax; Drug
Lead sponsor: Multiple Sclerosis Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Anesthetic Topical Adhesive Synera; Drug
Lead sponsor: Brown, Theodore R., M.D., MPH; Individual
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Multiple Sclerosis
Interventions: Interferon beta 1a, oral doxycycline; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Multiple Sclerosis
Interventions: Rebif®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: Up to 18 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Fingolimod, Disease Modifying therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 122
States / cities: Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 111 more

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b; Drug
Lead sponsor: Teva Neuroscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Swartz Creek, Michigan • Columbus, Ohio • Carnegie, Pennsylvania

Search by objective public record fields.

Pulse ACTH vs. MP for MS

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Therapy Optimization in Multiple Sclerosis (MS)